Safety and Efficacy of Balloon Pulmonary Angioplasty in China
Recruiting now
Conditions studied: Chronic Thromboembolic Pulmonary Hypertension
In brief
Balloon pulmonary angioplasty (BPA) is a potential treatment for non-operable patients with chronic thromboembolic pulmonary hypertension (CTEPH). The aim of this study was to evaluate the safety and efficacy of BPA in CTEPH patients not amenable to pulmonary endarterectomy(PEA) or suffered from persistent CTEPH after PEA.
Key facts
- Study ID
- NCT04206852
- Run by
- Chinese Pulmonary Vascular Disease Research Group
- People needed
- 200
- Starts
- 2018-05-11
- Expected to finish
- 2028-05-11
- Last updated by the study team
- 2023-12-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- diagnosed with CTEPH according to ESC Guidelines (1) Mean PAP ≥ 25mmHg at rest; or if mean PAP < 25mmHg at rest, have exercise limitations from chronic thromboembolic disease (2)Abnormal ventilation perfusion lung scanning (VQ) scan, pulmonary angiogram, computer tomographic pulmonary angiogram, or magnetic resonance pulmonary angiogram confirming chronic thromboembolic disease as recommended by standard guidelines
- Treatment with anticoagulation for ≥ 3 months before diagnosis of CTEPH
- Not amenable to pulmonary endarterectomy
- Willing to provide informed consent
You may not qualify if…
- Patients unwilling or unable to provide written consent for participation in the study.
- Impossible to follow up.
Where it is running
- center of pulmonary vascular disease, Fuwai hospital — Beijing, China (enrolling)
- Chinese Academy of Medical Sciences Fuwai hospital — Beijing, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.